SHARE EXCHANGE AGREEMENT Among: SINOBIOPHARMA, INC. And: DONGYING PHARMACEUTICAL CO, LIMITED And: THE SHAREHOLDERS OF DONGYING PHARMACEUTICAL CO, LIMITED Notice to the Shareholder of Dongying Pharmaceutical Co, Limited: The Shareholders of Dongying...Share Exchange Agreement • August 22nd, 2008 • Sinobiopharma, Inc. • Periodicals: publishing or publishing & printing • Nevada
Contract Type FiledAugust 22nd, 2008 Company Industry JurisdictionSINOBIOPHARMA INC., a corporation organized under the laws of the State of Nevada and having an address for notice and delivery located at 2820 W. Charleston Blvd., Suite 22, Las Vegas, Nevada 89102
SHARE PURCHASE AGREEMENTShare Purchase Agreement • August 22nd, 2008 • Sinobiopharma, Inc. • Periodicals: publishing or publishing & printing • British Columbia
Contract Type FiledAugust 22nd, 2008 Company Industry JurisdictionSINOBIOPHARMA, INC., a company incorporated under the laws of the State of Nevada, having an address for notice and deliver at 2820 West Charleston Boulevard, Suite 22, Las Vegas, Nevada, 89102
DONGYING PHARMACEUTICAL CO, LIMITED c/o 1225 Prince’s Building Hong KongAgreement to Cancel Shares • August 22nd, 2008 • Sinobiopharma, Inc. • Periodicals: publishing or publishing & printing • British Columbia
Contract Type FiledAugust 22nd, 2008 Company Industry JurisdictionSubject to and in accordance with the terms and conditions contained herein, this binding letter agreement (the “Agreement”) will set forth the basic understanding, terms and conditions relating to the cancellation of 59,000,500 of the 62,500,500 shares of common stock of the Company registered in the name of Jianguo Wang upon completion of the share exchange agreement between the Company, Dongying BVI and all the shareholders of Dongying BVI (the “Share Exchange Agreement”), whereby the Company will acquire 100% of the issued and outstanding shares of Dongying BVI. Such cancellation by Jianguo Wang is to: (i) encourage the shareholders of Dongying BVI to enter into the Share Exchange Agreement; (ii) allow Dr. Le-qun Lee Huang to be the largest shareholder in the Company; and (iii) encourage equity investment into the Company.